Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives

CAROL A. HITCHON, FATIHA CHANDAD, ELIZABETH D. FERUCCI, ANNEMIEK WILLEMZE, ANDREEA IOAN-FACSINAY, DIANE van der WOUDE, JANET MARKLAND, DAVID ROBINSON, BRENDA ELIAS, MARIANNA NEWKIRK, RENE M. TOES, TOM W.J. HUIZINGA and HANI S. EL-GABALAWY
The Journal of Rheumatology June 2010, 37 (6) 1105-1112; DOI: https://doi.org/10.3899/jrheum.091323
CAROL A. HITCHON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FATIHA CHANDAD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELIZABETH D. FERUCCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNEMIEK WILLEMZE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREEA IOAN-FACSINAY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIANE van der WOUDE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JANET MARKLAND
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID ROBINSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRENDA ELIAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIANNA NEWKIRK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RENE M. TOES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOM W.J. HUIZINGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANI S. EL-GABALAWY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elgabalh@cc.umanitoba.ca
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Anticitrullinated protein antibodies (ACPA) are relatively specific for rheumatoid arthritis (RA), and predate disease. The oral pathogen Porphyromonas gingivalis may play a role in breaking immune tolerance to citrullinated antigens. We studied a cohort of patients with RA and their relatives looking for associations between anti-P. gingivalis antibodies and ACPA.

Methods. Patients with RA (n = 82) and their relatives (n = 205) from a North American Native (NAN) population were studied, along with 47 NAN and 60 non-NAN controls. IgM and IgA rheumatoid factor (RF) were tested by nephelometry and ELISA. Second-generation anticyclic citrullinated peptide (anti-CCP2) isotypes and IgG anti-P. gingivalis lipopolysaccharides were tested by ELISA. HLA-DRB1 typing was performed by sequencing. Oral hygiene and smoking habits were assessed by questionnaires.

Results. Autoantibody frequency in patients with RA and relatives: ACPA 91% vs 19%, respectively; IgM RF 82% vs 17%; IgA RF 48% vs 22%. Anti-P. gingivalis levels were higher in patients with RA compared to relatives and controls (p = 0.005) and higher in ACPA-positive patients with RA than in ACPA-negative patients with RA (p = 0.04) and relatives (p < 0.001), but comparable in RF-positive and RF-negative patients and relatives. Poor oral hygiene and smoking were prevalent, but with no clear association with autoantibodies. Relatives with 2 shared-epitope alleles were more likely to be ACPA-positive (OR 2.5, p = 0.02).

Conclusion. In a genetically predisposed population of NAN patients with RA and their relatives, anti-P. gingivalis antibodies were associated with ACPA. These findings suggest that immune responses to P. gingivalis may be involved in breaking immune tolerance to citrullinated antigens.

  • PORPHYROMONAS GINGIVALIS
  • ANTICITRULLINATED PROTEIN ANTIBODIES
  • RHEUMATOID ARTHRITIS
  • PERIODONTITIS

Rheumatoid arthritis (RA) is a chronic inflammatory disorder centered in the synovial membrane of multiple joints. Currently, the etiology of RA remains unknown, although it has been suggested that gene-environment interactions play a substantial role in disease susceptibility1. Much is now known about genetic susceptibility to RA, with the HLA-DRB1 locus accounting for most of the genetic risk. Alleles of HLA-DRB1 encoding for the so-called shared-epitope (SE), a positively charged QK(R)RAA motif in the third hypervariable region of the molecule, confer RA disease susceptibility in multiple populations2,3.

The environmental factors that potentially interact with susceptibility genes to precipitate RA onset continue to be investigated. The best documented environmental factor is tobacco smoking, which has been shown in several studies4–9 to contribute to RA susceptibility. Importantly, smoking appears to contribute to disease susceptibility only in individuals who develop autoantibody-positive RA characterized by the presence of anticitrullinated protein antibodies (ACPA). There is a clustering of RA risk associated with smoking, carriage of SE alleles, and the presence of ACPA6,7,10.

A number of other environmental factors have been studied for their potential role in the onset and pathogenesis of RA. Recently, several studies have reported an association between RA and periodontitis (PD)11–13. It has been reported that patients with longstanding active RA have a significantly increased incidence of PD compared with healthy subjects, and patients with PD have a higher prevalence of RA than patients without PD13,14. A recent large cross-sectional survey of the US population [National Health and Nutrition Examination Survey (NHANES) III] confirmed the documented association between RA and PD15. Various hypotheses have been proposed to explain the mechanisms of the potential association between RA and PD13,16. One of these hypotheses suggests that RA and PD may share common pathogenetic processes including common HLA-DRB1 associations, shared cellular and humoral immune reactions, and highly similar inflammatory reactions12,15. In addition, many therapeutic strategies for RA are also effective in PD, including the use of antiinflammatory drugs and inhibitors of cytokines and matrix metalloproteinases17,18. Recently it has been proposed that Porphyromonas gingivalis, the major etiologic agent associated with the pathogenesis of PD, may be a particularly important factor in the association between RA and PD. This association is based on the presence of the enzyme peptidyl arginine deiminase (PAD), which allows P. gingivalis to generate citrullinated peptides in vivo13. It is thus hypothesized that in a genetically susceptible (SE-positive) individual, such citrullinated peptides may interrupt tolerance to endogenous citrullinated antigens, resulting in the generation of an immune response to citrullinated self-antigens.

We have studied a unique cohort of North American Native (NAN) people from central Canada and have shown that the Cree/Ojibway population has some of the highest prevalence rates of RA in the world19. Moreover, this population, with frequent multicase families, demonstrates an early age of RA onset, high levels of ACPA and rheumatoid factor (RF), and a high population prevalence of SE alleles20,21. Thus, this population is an ideal model for studying disease risk in the family members of patients with RA. We have shown that almost 20% of the first-degree relatives of NAN patients with RA have detectable ACPA21, although at this point it remains unclear whether these ACPA-positive individuals will ultimately develop RA, and over what timeframe.

Our aim was to test the hypothesis that the humoral immune response to P. gingivalis is associated with the presence of ACPA both in patients with well established RA and in their ACPA- positive disease-free relatives. We also attempted to relate the immune serology to RA and to oral health habits and smoking history. Our data indicate that there is indeed a clear association between the humoral immune response to P. gingivalis and the presence of ACPA both in patients and disease-free relatives.

MATERIALS AND METHODS

Patients, relatives, and controls

Patients with RA were recruited from a Cree and Ojibway NAN population in central Canada. Patients visiting rheumatology clinics in urban (Winnipeg, Saskatoon) and rural (Norway House, St. Theresa’s Point) locations were approached to bring along unaffected relatives who were willing to participate in this study. All study subjects were over 18 years of age. The unaffected population consisted mainly of first-degree relatives (76%) and was composed of siblings and offspring, with the remainder being second-degree relatives (cousins, nieces, nephews). Eighty-five families were included in the study, comprising 82 probands and 205 relatives. All relatives had at least 1 family member with RA, but some relatives did not have their affiliated RA proband(s) included in the study, thus accounting for the larger number of families than probands. Additionally, 47 unrelated healthy controls were recruited from the same populations. Sixty white controls were randomly selected from a serum bank of healthy individuals prior to undergoing vaccination for overseas travel. The control populations were not closely matched for age and sex.

The clinical and serological characteristics of the patients with RA and relatives are described in Table 1. RA was diagnosed according to the American College of Rheumatology criteria22. Clinical assessment of swollen, stiff, and painful joints of all patients and relatives was performed by a rheumatologist at the time of inclusion. Of the relatives, 8 presented with 1 or more swollen joints at inclusion, but did not meet criteria for RA or any other rheumatic disease, and were classified as having undifferentiated arthritis (UA). Analyses were undertaken with and without this small group of individuals with UA, and their inclusion did not affect the outcome or significance of each analysis. These individuals were analyzed as part of the unaffected relatives population. There was no difference in the demographic characteristics between the first-degree and second-degree relatives. In the patients with RA, radiographic erosions in hands and feet were assessed by review of the radiographs and/or radiograph reports, and were categorized as present or absent in each. The 47 unrelated controls had no swollen joints at inclusion and no first-degree relatives with RA.

View this table:
  • View inline
  • View popup
Table 1.

Demographics and autoantibody status of patients with rheumatoid arthritis and relatives. For the shared-epitope, these HLA-DRB1 alleles were tested: 0101, 0102, 0103, 0301, 0401, 0402, 0403, 0404, 0407, 0408, 0410, 0701, 0801, 0802, 0811, 0901, 1101, 1103, 1301, 1302, and 1402. Shared-epitope alleles: 0101, 0102, 0401, 0404, 0405, 0408, 0410, 1001, and 1402. Tender and swollen joint counts were based on 44-joint count; 8 relatives with joint swelling. Values are median (interquartile range) or percentage. Statistical associations tested by Mann-Whitney U or chi-square.

All participants gave written consent, and the Biomedical Research Ethics Boards of the University of Manitoba and the Band Councils of each rural community approved the protocol.

ACPA antibody isotype testing

Total IgG ACPA seropositivity was assayed by ELISA using a second-generation anti-CCP kit (CCP2; Inova Diagnostics, San Diego, CA, USA). Positive tests were defined as those with values ≥ 20 units, per the manufacturer’s specifications. ACPA isotypes (IgA, IgG1-4, and IgM) were measured in baseline serum samples of patients with RA, healthy relatives, and unrelated healthy controls, using CCP2 plates (Euro-Diagnostica, Arnhem, The Netherlands) and the ELISA mentioned21. A successive dilution of 1 reference standard, consisting of a pool of 20 ACPA-positive samples, was used in all plates. Distinct dilutions of this standard (IgA and IgM: 1:12.5; IgG1: 1:400; IgG2: 1:6.25; IgG3 and IgG4: 1:12.5) were defined as containing 1000 arbitrary units per ml (AU/ml).

Determination of cutoff values for ACPA ELISA

The level of specific antibodies in each serum sample was determined using the reference standard curve. Cutoff values for the citrullin-specific responses were calculated in each assay and were defined as 2 SD above the mean concentration of serum samples obtained from 30 healthy White controls. In case the concentrations of several control samples were below the detection limit of the ELISA, the cutoff was calculated as the lowest concentration situated on the ascending region of the standard curve. Borderline samples (with concentrations between 10 AU above and below the cutoff value) were tested at least twice for IgA ACPA and all IgG isotypes. All samples reacting with the citrullinated peptides in fine-specificity assays were retested. Only samples that were positive every time tested were considered positive.

RF measurements

IgM RF values reported throughout the study were determined by nephelometry. IgA RF and IgM RF were also measured by ELISA, using human IgG1 as the capture antigen, and F(ab’)2 fragments of peroxidase-conjugated antihuman IgA or IgM, as described23. The cutoffs used to assign positivity were based on 60 White controls. The IgM RF values as determined by ELISA were comparable to those obtained by nephelometry.

Humoral immune response against P. gingivalis antigens

Lipopolysaccharides (LPS) of P. gingivalis were isolated by the method described by Darveau and Hancock24. The amount of contaminating proteins was evaluated using a protein assay kit (Biorad Laboratories, Mississauga, ON, Canada) and was < 0.001%.

Antibodies to P. gingivalis LPS and ELISA index calculations

IgG antibodies specific to LPS of P. gingivalis were measured using ELISA. The wells of 96-well flat-bottom microtiter plates were coated in triplicate with LPS of P. gingivalis. After washing and blocking the plates, serum samples were added to individual wells and specific human IgG antibodies were detected with an alkaline phosphatase-conjugated antihuman immunoglobulin. The absorbance was read at 405 nm using an ELISA plate reader. Each assay included a conjugate control, a substrate control, a conjugate-substrate reactivity control, and a serially diluted reference serum control. The results were expressed as an ELISA Index (EI), which was the mean OD405 of a given serum divided by the mean OD405 of the calibrator (reference serum). Positive calibrator and negative assay controls were included in each run to control for intraassay and interassay variation. Values were reported as median (interquartile range; IQR).

Smoking and oral health questionnaires

Subjects answered questionnaires regarding smoking and oral hygiene habits. Smoking was assessed by the duration and the number of smoked cigarettes [i.e., 1 cigarette/day for 3 or more months, at least 5 cigarettes in the past 6 months (current smoker); 1–5 cigarettes/month, 1–5 cigarettes/week, fewer than 10 cigarettes/day, half to 1 pack/day, or more than 1 pack/day). Oral hygiene habits were assessed by asking participants how many times a week they brushed and flossed their teeth, on a scale of never, 1–6 times, 7–14 times, or 15+ times. They also were asked how often they see a dentist, on a scale of never, 1–2 times/year, or 2+ times/year.

Statistical analysis

Statistical analyses were performed using the SPSS (version 14.0) software. Data distribution was tested for normality, and non-normally distributed data reported as median and IQR. Mann-Whitney U or Kruskal-Wallis tests were used to compare age, joint counts, C-reactive protein, and levels of P. gingivalis, ACPA isotypes, and RF. Differences in the distribution of the ACPA isotypes between healthy relatives and patients with RA and associations with dental habits and smoking were calculated using the chi-squared test. The chi-squared test was also used for calculating OR with 95% CI, and p values for the association of SE with ACPA. When a cell contained < 5 individuals, Fisher’s exact 2-tailed p value was calculated. A p value < 0.05 and a 95% CI that excluded the value of 1 were considered significant.

RESULTS

The clinical characteristics of the study subjects are shown in Table 1. The relatives were younger than patients, and less likely to be women. As reported21, 91% of patients and 19% of relatives had ACPA of at least 1 isotype, and patients had a greater number of ACPA isotypes and higher ACPA levels. Similar findings were seen using a CCP2 kit that measures only total IgG ACPA (RA 81% vs relatives 5% positive). There were no significant differences between patients and relatives in the presence of SE alleles (81% vs 73%) or in the presence of 2 copies of SE alleles (33% vs 23%), although both tended to be higher in patients. Relatives with 2 SE alleles were more likely to be ACPA-positive (OR 2.5, p = 0.02). HLA-DRB1*0404 and *1402 are the most prevalent SE alleles in this population20.

IgG antibody responses to P. gingivalis LPS were measured in the sera from patients with RA (n = 82), relatives (n = 205), unrelated NAN controls from the same population (n = 47), and non-NAN controls from a serum bank (n = 60). Five patients with RA and 9 relatives had samples that could not be analyzed for anti-P. gingivalis LPS responses, but these individuals did not differ significantly from the remainder of the cohort. As shown in Figure 1, anti-P. gingivalis levels were higher in the patients with RA compared to the other groups combined [median (IQR) 42 (30) vs 33 (19) AU; p = 0.001], but there were no differences between the relatives and the 2 control groups. Patients with RA with and without erosions did not differ in anti-P. gingivalis levels (data not shown).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Levels of anti-P. gingivalis ELISA index in patients with RA, relatives, First Nations (NAN) controls, and non-NAN controls. Numbers represent arbitrary units derived from ELISA optical densities.

We next looked specifically at the association between anti-P. gingivalis responses and ACPA serology in patients with RA and relatives. Levels of ACPA isotypes (IgG1-4, IgA, IgM) were analyzed by ELISA as described. Individuals were considered ACPA-positive if their ELISA levels were above the cutoff threshold established for any of the ACPA isotypes. The data in Figure 2A indicate that anti-P. gingivalis responses were significantly higher in ACPA-positive than in ACPA-negative individuals. In the unaffected relatives group, ACPA-positive individuals had higher anti-P. gingivalis LPS levels [median (IQR) 44 (21) vs 32 (22) AU; p < 0.0001] compared to ACPA-negative relatives. In the group of patients with RA, ACPA-positive individuals had higher anti-P gingivalis levels compared to ACPA-negative patients with RA [median (IQR) 43 (29) vs 25 (28) AU; p = 0.04] even though only 6/82 patients (7%) were ACPA-negative. There was no difference in anti-P. gingivalis levels between ACPA-positive relatives and ACPA-positive patients with RA. Moreover, of the ACPA-positive relatives and patients, there were no significant differences in the anti-P. gingivalis levels for each individual isotype (data not shown). These data indicate that there is an association between humoral immune responses to P. gingivalis and ACPA positivity, and that this association is independent of having RA itself. In contrast, there was no association between anti-P. gingivalis antibody levels and RF, as shown in Figure 2B. Further, as shown in Table 2, after stratifying for ACPA in the IgM RF-positive or IgA RF-negative individuals, the association of P. gingivalis levels with ACPA remained in the relatives, but not in the patients with RA. In contrast, in ACPA-positive individuals there were no associations of IgM or IgA RF with anti-P. gingivalis levels. This supports a primary association between ACPA positivity and P. gingivalis levels.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Levels of anti-P. gingivalis in relatives and patients with RA according to the presence of (A) anticitrullinated protein antibodies (ACPA) or (B) rheumatoid factor (RF). Numbers represent arbitrary units derived from ELISA optical densities.

View this table:
  • View inline
  • View popup
Table 2.

Association of anti-P. gingivalis lipopolysaccharide levels and IgM RF, IgA RF, and ACPA. Values are median (interquartile range) of anti-P. gingivalis levels in patients with RA or their relatives with IgM rheumatoid factor (IgM RF), IgA RF, and/or anticitrullinated protein antibodies (ACPA); p values were calculated using Mann-Whitney U tests.

We next examined whether poor oral health habits were associated with immune responses to P. gingivalis, with the presence of ACPA, or with RA. A subset of subjects (56 patients; 141 relatives) answered a detailed questionnaire regarding oral hygiene habits. There were no significant clinical, serological, or anti-P. gingivalis antibody level differences between subjects who did or did not answer the oral hygiene questions. As shown in Table 3, patients with RA were more likely to have dentures (37% vs 15%; p < 0.001) compared to relatives, and visited the dentist less often. Both groups had similar oral hygiene habits, with 44% of patients and 55% of relatives brushing at least once daily and > 60% flossing. There were no associations between oral hygiene habits and ACPA positivity apart from an increased tendency to have dentures.

View this table:
  • View inline
  • View popup
Table 3.

Self-reported dental hygiene and smoking habits and their associations with ACPA and levels of anti-P. gingivalis lipopolysaccharide. Values are number of subjects with RA or their relatives reporting habit. Anti-P. gingivalis levels reported as median (interquartile range) of arbitrary units in patients with RA and relatives.

Since smoking has been associated in studies with both ACPA5,7 and PD25,26, we investigated whether there was any association between smoking habits and the humoral immune response to P. gingivalis and to ACPA positivity. The data shown in Table 3 indicate that 75% of patients with RA and 74% of relatives had smoked at least 1 cigarette/day for at least 3 months, while 22% of patients with RA and 23% of relatives smoked more than a half pack/day. On the basis of these similar high smoking rates in both patients with RA and relatives, no clear association could be established between smoking-related measurements and the immune response to P. gingivalis or ACPA positivity. Moreover, no association was seen between smoking, SE (single or 2 copies), and ACPA of any isotype in patients with RA or relatives. There was no association between anti-P. gingivalis levels and SE.

DISCUSSION

There has been a well documented association between RA and PD since the 1950s, although the biological basis for this association has not been clearly elucidated. This epidemiological association was confirmed in the NHANES III study, which suggested an OR 1.82, 95% CI 1.04–3.2015. It has been hypothesized that this association may be based on the capacity of P. gingivalis, the major etiological agent of periodontitis, to express a PAD, an enzyme responsible for posttranslational citrullination of arginine residues13. This enzymatic activity potentially exposes affected individuals to citrullinated antigens, and in the context of the appropriate immunogenetic background, would predispose to the development of ACPA. ACPA are known to be relatively specific for RA, to precede disease onset, and to potentially be involved in the pathogenesis of RA synovitis27,28.

We investigated whether there was an association between immune responses to the periodontal pathogen P. gingivalis and the presence of RA and/or ACPA. Sera from a cohort of NAN patients with RA and their unaffected relatives who are at risk for disease development21 were analyzed for ACPA, RF, and specific IgG antibodies to P. gingivalis LPS. We demonstrate that serum levels of the anti-P. gingivalis LPS were higher in patients with RA compared to their relatives, and to 2 distinct control groups, 1 of which was from the same population. Importantly, the data reveal that the immune responses to P. gingivalis LPS were significantly higher in ACPA-positive than in ACPA-negative individuals, irrespective of whether they had RA.

Mikuls, et al recently compared the levels of anti-P. gingivalis antibodies in patients with RA, PD, and healthy controls29. These data showed that the levels of anti-P. gingivalis antibodies were highest in PD, lowest in controls, and intermediate in RA. This study also showed an association between the levels of anti-P. gingivalis antibodies and levels of IgM and IgG2 ACPA, but not RF, in the patients with RA. Our study is consistent with these data. It should be pointed out that we tested the antibody response to a more restricted P. gingivalis antigen, LPS, while the Mikuls study evaluated antibody responses to a broader antigenic spectrum using lysates of whole organisms.

We present data from a unique cohort of the disease-free relatives of patients with RA who have a high prevalence of ACPA. This allowed us to address a key question: whether antibody responses to P. gingivalis are associated with ACPA outside the context of RA. The data clearly indicate that this is the case. Moreover, this association was specific for ACPA as there was no association with RF. The lack of association between antibody responses to P. gingivalis and RF is also reported in the Mikuls study29. The findings are consistent with the hypothesis that immune responses to P. gingivalis are in some way involved with the breaking of immune tolerance to citrullinated antigens, as indicated by the presence of ACPA. Since P. gingivalis expresses PAD and can potentially citrullinate peptides in vivo, host immune responses to such neoantigens may trigger autoimmunity to endogenous citrullinated antigens through mechanisms such as molecular mimicry and epitope-spreading13.

It is currently unknown which peptides or proteins may constitute the most important in vivo antigen for ACPA, but several citrullinated proteins have been reported as possible targets, including citrullinated fibrinogen, vimentin, type II collagen, and α-enolase30–33. Citrullinated α-enolase peptide 1 (CEP-1), the immunodominant peptide of human α-enolase, has 82% homology with enolase from P. gingivalis, and anti-CEP1 antibodies have been described to be cross-reactive with the bacterial enzyme34. On the basis of these data, it was concluded that bacterial infection with P. gingivalis may play a role in priming the ACPA response. Although antibody responses to CEP-1 were not measured as part of our study, we have used a different α-enolase peptide in our fine specificity studies21. This peptide (called C6) was recognized by 14% of NAN patients with RA and none of the relatives, thus precluding a meaningful analysis in the context of our study. Large-scale studies and longitudinal followup of this cohort, to determine which of the ACPA-positive relatives may develop RA, will be required to more clearly elucidate the possible associations between ACPA, antienolase reactivity, and P. gingivalis.

We attempted to determine whether oral hygiene and smoking were associated with RA, ACPA, and with immune responses to P. gingivalis. It is known that smoking and poor oral health habits both increase the risk of PD. Smoking is a risk factor for PD possibly through the effects of nicotine on inflammatory cytokine profiles35,36 and matrix metalloproteinase activity37,38 or potentially even through direct effects on P. gingivalis gene expression39. We did find a high prevalence of both smoking and poor oral health habits in the study population based on self-report questionnaire data; however, we could not define a clear association between these factors and the presence of either RA or ACPA. Studies of NAN populations from a similar geographical area have shown a high prevalence of PD that is associated with poor dental hygiene habits40. Further studies, including formal dental assessments and sampling, are under way to confirm the presence and extent of PD in this population.

The reported association between immune responses to the oral pathogen P. gingivalis and the presence of ACPA in a population with a high background prevalence of RA-pre-disposing HLA-DRB1 alleles is consistent with a gene-environment interaction that may result in breaking self-tolerance to citrullinated antigens and/or amplification of these autoimmune responses, and ultimately leading to the development of RA. It should be added that the sample size tested in this study precluded an analysis of such as gene-environment interaction. Moreover, the demonstrated association between P. gingivalis and ACPA may reflect a broader association with periodontitis, which was not addressed by systematic oral examinations. While further studies are needed to support this association and to assess longitudinal outcomes in high-risk individuals, we suggest that interventions directed at modulating these environmental risk factors, such as improved oral health and smoking cessation, may play an important role in reducing or delaying the onset of future RA.

Acknowledgments

We thank the First Nations communities, their chiefs, and band councils for support during this study.

Footnotes

  • Supported by a research grant from the Canadian Institutes of Health Research, MOP 77000.

  • Accepted for publication February 3, 2010.

REFERENCES

  1. 1.↵
    1. Klareskog L,
    2. Padyukov L,
    3. Lorentzen J,
    4. Alfredsson L
    . Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2:425–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kochi Y,
    2. Suzuki A,
    3. Yamada R,
    4. Yamamoto K
    . Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009;32:158–62.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Oen K,
    2. Robinson DB,
    3. Nickerson P,
    4. Katz SJ,
    5. Cheang M,
    6. Peschken CA,
    7. et al.
    Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes. J Rheumatol 2005;32:983–91.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Heliovaara M,
    2. Aho K,
    3. Aromaa A,
    4. Knekt P,
    5. Reunanen A
    . Smoking and risk of rheumatoid arthritis. J Rheumatol 1993;20:1830–5.
    OpenUrlPubMed
  5. 5.↵
    1. Klareskog L,
    2. Stolt P,
    3. Lundberg K,
    4. Kallberg H,
    5. Bengtsson C,
    6. Grunewald J,
    7. et al.
    A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38–46.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lundstrom E,
    2. Kallberg H,
    3. Alfredsson L,
    4. Klareskog L,
    5. Padyukov L
    . Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009;60:1597–603.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pedersen M,
    2. Jacobsen S,
    3. Garred P,
    4. Madsen HO,
    5. Klarlund M,
    6. Svejgaard A,
    7. et al.
    Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007;56:1446–53.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Silman AJ,
    2. Newman J,
    3. MacGregor AJ
    . Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996;39:732–5.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Stolt P,
    2. Bengtsson C,
    3. Nordmark B,
    4. Lindblad S,
    5. Lundberg I,
    6. Klareskog L,
    7. et al.
    Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835–41.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. van der Helm-van Mil AH,
    2. Verpoort KN,
    3. le Cessie S,
    4. Huizinga TW,
    5. de Vries RR,
    6. Toes RE
    . The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007;56:425–32.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Bartold PM,
    2. Marshall RI,
    3. Haynes DR
    . Periodontitis and rheumatoid arthritis: a review. J Periodontol 2005;76:2066–74.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Marotte H,
    2. Farge P,
    3. Gaudin P,
    4. Alexandre C,
    5. Mougin B,
    6. Miossec P
    . The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006;65:905–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Rosenstein ED,
    2. Greenwald RA,
    3. Kushner LJ,
    4. Weissmann G
    . Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004;28:311–8.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Mercado FB,
    2. Marshall RI,
    3. Klestov AC,
    4. Bartold PM
    . Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779–87.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. de Pablo P,
    2. Dietrich T,
    3. McAlindon TE
    . Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 2008;35:70–6.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ribeiro J,
    2. Leao A,
    3. Novaes AB
    . Periodontal infection as a possible severity factor for rheumatoid arthritis. J Clin Periodontol 2005;32:412–6.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Greenwald RA,
    2. Kirkwood K
    . Adult periodontitis as a model for rheumatoid arthritis (with emphasis on treatment strategies). J Rheumatol 1999;26:1650–3.
    OpenUrlPubMed
  18. 18.↵
    1. Rosenstein ED,
    2. Kushner LJ,
    3. Kramer N,
    4. Kazandjian G
    . Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis. Prostaglandins Leukot Essent Fatty Acids 2003;68:213–8.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Peschken CA,
    2. Esdaile JM
    . Rheumatic diseases in North America’s indigenous peoples. Semin Arthritis Rheum 1999;28:368–91.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. El-Gabalawy HS,
    2. Robinson DB,
    3. Hart D,
    4. Elias B,
    5. Markland J,
    6. Peschken CA,
    7. et al.
    Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol 2009;36:1130–5.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Ioan-Facsinay A,
    2. Willemze A,
    3. Robinson DB,
    4. Peschken CA,
    5. Markland J,
    6. van der Woude D,
    7. et al.
    Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000–8.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Newkirk MM,
    2. Goldbach-Mansky R,
    3. Senior BW,
    4. Klippel J,
    5. Schumacher HR Jr,
    6. El-Gabalawy HS
    . Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology 2005;44:1433–41.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Darveau RP,
    2. Hancock RE
    . Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 1983;155:831–8.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Do LG,
    2. Slade GD,
    3. Roberts-Thomson KF,
    4. Sanders AE
    . Smoking-attributable periodontal disease in the Australian adult population. J Clin Periodontol 2008;35:398–404.
    OpenUrlPubMed
  26. 26.↵
    1. Preshaw PM,
    2. Seymour RA,
    3. Heasman PA
    . Current concepts in periodontal pathogenesis. Dent Update 2004;31:570–8.
    OpenUrlPubMed
  27. 27.↵
    1. Nielen MM,
    2. van Schaardenburg D,
    3. Reesink HW,
    4. van de Stadt RJ,
    5. van der Horst-Bruinsma IE,
    6. de Koning MH,
    7. et al.
    Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380–6.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Rantapaa-Dahlqvist S,
    2. de Jong BA,
    3. Berglin E,
    4. Hallmans G,
    5. Wadell G,
    6. Stenlund H,
    7. et al.
    Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741–9.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Mikuls TR,
    2. Payne JB,
    3. Reinhardt RA,
    4. Thiele GM,
    5. Maziarz E,
    6. Cannella AC,
    7. et al.
    Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009;9:38–42.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Burkhardt H,
    2. Sehnert B,
    3. Bockermann R,
    4. Engstrom A,
    5. Kalden JR,
    6. Holmdahl R
    . Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005;35:1643–52.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Kinloch A,
    2. Tatzer V,
    3. Wait R,
    4. Peston D,
    5. Lundberg K,
    6. Donatien P,
    7. et al.
    Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421–9.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Masson-Bessiere C,
    2. Sebbag M,
    3. Girbal-Neuhauser E,
    4. Nogueira L,
    5. Vincent C,
    6. Senshu T,
    7. et al.
    The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177–84.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Vossenaar ER,
    2. Despres N,
    3. Lapointe E,
    4. van der Heijden A,
    5. Lora M,
    6. Senshu T,
    7. et al.
    Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142–50.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Lundberg K,
    2. Kinloch A,
    3. Fisher BA,
    4. Wegner N,
    5. Wait R,
    6. Charles P,
    7. et al.
    Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008;58:3009–19.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. de Heens GL,
    2. Kikkert R,
    3. Aarden LA,
    4. van der Velden U,
    5. Loos BG
    . Effects of smoking on the ex vivo cytokine production in periodontitis. J Periodontal Res 2009;44:28–34.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. de Heens GL,
    2. van der Velden U,
    3. Loos BG
    . Cigarette smoking enhances T cell activation and a Th2 immune response; an aspect of the pathophysiology in periodontal disease. Cytokine 2009;47:157–61.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Zhang W,
    2. Song F,
    3. Windsor LJ
    . Cigarette smoke condensate affects the collagen-degrading ability of human gingival fibroblasts. J Periodontal Res 2009;44:704–13.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Ho YC,
    2. Yang SF,
    3. Huang FM,
    4. Chang YC
    . Up-regulation of osteolytic mediators in human osteosarcoma cells stimulated with nicotine. J Periodontal Res 2009;44:760–6.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Bagaitkar J,
    2. Williams LR,
    3. Renaud DE,
    4. Bemakanakere MR,
    5. Martin M,
    6. Scott DA,
    7. et al.
    Tobacco-induced alterations to Porphyromonas gingivalis-host interactions. Environ Microbiol 2009;11:1242–53.
    OpenUrlPubMed
  40. 40.↵
    1. Brothwell D,
    2. Ghiabi E
    . Periodontal health status of the Sandy Bay First Nation in Manitoba, Canada. Int J Circumpolar Health 2009;68:23–33.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 6
1 Jun 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives
CAROL A. HITCHON, FATIHA CHANDAD, ELIZABETH D. FERUCCI, ANNEMIEK WILLEMZE, ANDREEA IOAN-FACSINAY, DIANE van der WOUDE, JANET MARKLAND, DAVID ROBINSON, BRENDA ELIAS, MARIANNA NEWKIRK, RENE M. TOES, TOM W.J. HUIZINGA, HANI S. EL-GABALAWY
The Journal of Rheumatology Jun 2010, 37 (6) 1105-1112; DOI: 10.3899/jrheum.091323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives
CAROL A. HITCHON, FATIHA CHANDAD, ELIZABETH D. FERUCCI, ANNEMIEK WILLEMZE, ANDREEA IOAN-FACSINAY, DIANE van der WOUDE, JANET MARKLAND, DAVID ROBINSON, BRENDA ELIAS, MARIANNA NEWKIRK, RENE M. TOES, TOM W.J. HUIZINGA, HANI S. EL-GABALAWY
The Journal of Rheumatology Jun 2010, 37 (6) 1105-1112; DOI: 10.3899/jrheum.091323
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study
  • GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting
  • Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire